Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Kewalramani cast the moment as an “opportunity to change the paradigm of acute pain management and establish a new standard of care.” Still, Journavx faces some hurdles in winning over ...

Dean Maglaris, CEO of Cytogel Pharma Cytogel is inspired by broader progress & committed to innovating in the field of pain management, s ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...